Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Methyl salicylate and l-menthol transdermal patch (FS-67) is an over-the-counter topical analgesic product developed by Hisamitsu Pharmaceutical. It is marketed under the brand names Salonpas Pain Relief Patch and Salonpas Arthritis Pain. The patch contains methyl salicylate (10%) and l-menthol (3%) as active ingredients. Its mechanism of action involves local counterirritation to relieve mild to moderate aches and pains of muscles and joints associated with arthritis, sprains, bruises, or simple backache. The product was the first FDA-approved OTC topical analgesic patch in its category in the United States. Clinical studies have shown it to be safe for adults; however, efficacy was not demonstrated in pediatric populations aged 13–17 years for ankle sprain pain relief[1][2][6][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on methyl salicylate and l-menthol transdermal patch.